JP2016185981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185981A5 JP2016185981A5 JP2016137228A JP2016137228A JP2016185981A5 JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5 JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102100034577 Desmoglein-3 Human genes 0.000 claims 2
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006221230 | 2006-08-14 | ||
| JP2006221230 | 2006-08-14 | ||
| JP2007019108 | 2007-01-30 | ||
| JP2007019108 | 2007-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014175480A Division JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185981A JP2016185981A (ja) | 2016-10-27 |
| JP2016185981A5 true JP2016185981A5 (enExample) | 2017-04-13 |
| JP6162864B2 JP6162864B2 (ja) | 2017-07-12 |
Family
ID=39082111
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529863A Active JP5317697B2 (ja) | 2006-08-14 | 2007-08-14 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2013043041A Active JP5651726B2 (ja) | 2006-08-14 | 2013-03-05 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2014175480A Active JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2016137228A Active JP6162864B2 (ja) | 2006-08-14 | 2016-07-12 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529863A Active JP5317697B2 (ja) | 2006-08-14 | 2007-08-14 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2013043041A Active JP5651726B2 (ja) | 2006-08-14 | 2013-03-05 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| JP2014175480A Active JP5972325B2 (ja) | 2006-08-14 | 2014-08-29 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100092457A1 (enExample) |
| EP (3) | EP2548576B1 (enExample) |
| JP (4) | JP5317697B2 (enExample) |
| AU (1) | AU2007285217B2 (enExample) |
| BR (1) | BRPI0713086A2 (enExample) |
| CA (1) | CA2658050A1 (enExample) |
| WO (1) | WO2008020586A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158385B2 (en) * | 2002-10-11 | 2012-04-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20080206229A1 (en) * | 2003-12-12 | 2008-08-28 | Koichiro Ono | Modified Antibodies Recognizing Receptor Trimers or Higher Multimers |
| JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US20070280951A1 (en) * | 2003-12-12 | 2007-12-06 | Naoki Kimura | Cell Death Inducing Agents |
| JP4799405B2 (ja) * | 2004-04-09 | 2011-10-26 | 中外製薬株式会社 | 細胞死誘導剤 |
| WO2006106903A1 (ja) * | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
| US20090022687A1 (en) * | 2005-05-18 | 2009-01-22 | Chugai Seiyaku Kabushiki Kaisha | Novel Pharmaceuticals That Use Anti-HLA Antibodies |
| JP5068167B2 (ja) * | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
| CN101262885B (zh) * | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| MX2009000487A (es) * | 2006-07-13 | 2009-01-27 | Chugai Pharmaceutical Co Ltd | Inductor de muerte celular. |
| JP5317697B2 (ja) | 2006-08-14 | 2013-10-16 | 中外製薬株式会社 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| WO2008085987A2 (en) * | 2007-01-09 | 2008-07-17 | The Trustees Of The University Of Pennsylvania | Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| US8481688B2 (en) | 2010-05-11 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
| CN105884895B (zh) * | 2010-09-28 | 2019-12-13 | 株式会社Nb健康研究所 | 抗人ccr7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体 |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| JP5221825B1 (ja) * | 2012-10-09 | 2013-06-26 | コニカミノルタホールディングス株式会社 | 肺扁平上皮癌の検出方法 |
| WO2014100220A2 (en) * | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
| DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
| WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
| EP3568158A4 (en) | 2017-01-11 | 2020-11-18 | The Board of Trustees of the Leland Stanford Junior University | R-SPONDIN SUBSTITUTION MOLECULES (RSPO) |
| CN110234662A (zh) | 2017-01-26 | 2019-09-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| JP7429192B2 (ja) | 2018-04-06 | 2024-02-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用 |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| CN113476601B (zh) * | 2021-08-24 | 2022-05-20 | 知佰幸细胞库(浙江)有限公司 | 干细胞细胞因子联合海藻多糖制备的药物或化妆品 |
| JP2024546842A (ja) * | 2021-12-14 | 2024-12-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 疾患を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Industrial Co Ltd | Semiconductor laser protective circuit |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| EP1075494A2 (en) | 1998-05-05 | 2001-02-14 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| WO2002031140A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions |
| JP2005500018A (ja) | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | ＧｎＴＩＩＩと同時発現する組換え抗体 |
| EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2003020769A1 (en) | 2001-09-04 | 2003-03-13 | Keio University | Pemphigus monoclonal antibody |
| US7750204B2 (en) | 2002-06-05 | 2010-07-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibody |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| US20060057559A1 (en) * | 2004-06-23 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | High-throughput cell migration screening assay |
| US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
| JP5317697B2 (ja) | 2006-08-14 | 2013-10-16 | 中外製薬株式会社 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
-
2007
- 2007-08-14 JP JP2008529863A patent/JP5317697B2/ja active Active
- 2007-08-14 US US12/308,695 patent/US20100092457A1/en not_active Abandoned
- 2007-08-14 EP EP12173653.2A patent/EP2548576B1/en active Active
- 2007-08-14 CA CA002658050A patent/CA2658050A1/en not_active Withdrawn
- 2007-08-14 WO PCT/JP2007/065834 patent/WO2008020586A1/ja not_active Ceased
- 2007-08-14 AU AU2007285217A patent/AU2007285217B2/en not_active Expired - Fee Related
- 2007-08-14 BR BRPI0713086-4A patent/BRPI0713086A2/pt not_active Application Discontinuation
- 2007-08-14 EP EP07792477.7A patent/EP2050466B1/en active Active
- 2007-08-14 EP EP16178652.0A patent/EP3111955B1/en active Active
-
2013
- 2013-03-05 JP JP2013043041A patent/JP5651726B2/ja active Active
-
2014
- 2014-08-29 JP JP2014175480A patent/JP5972325B2/ja active Active
-
2016
- 2016-07-12 JP JP2016137228A patent/JP6162864B2/ja active Active
-
2017
- 2017-02-10 US US15/430,031 patent/US10696743B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185981A5 (enExample) | ||
| JP2020501532A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| JP2020022464A5 (enExample) | ||
| JP2018504907A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| MX392340B (es) | Anticuerpo anti cd73 humana. | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2013539361A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2012116856A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2014012688A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| JP2012502649A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2011526480A5 (enExample) | ||
| JP2017534262A5 (enExample) | ||
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| JP2012034692A5 (enExample) | ||
| JP2014518883A5 (enExample) |